Phase 2 N=30 Role Of Phosphorus And FGF 23 In Patients With Dent Disease
Dent Disease
Primary: Change in Urine Total Protein — 1681; 59 mg/day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 An Adaptive Treatment Strategy for Adolescent Depression-Continuation
Adolescent Depression
Primary: Children's Depression Rating Scale-Revised (CDRS-R) — 32.38; 26.67; 51; 45 score on a scale
Phase 2 N=22 Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Multiple Endocrine Neoplasia Type 1 · Pancreatic Neuroendocrine Carcinoma
Primary: Objective Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 — 9.5 percentage of participants
Phase 2 N=58 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Adult Nasal Type Extranodal NK/T-cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma
Primary: Number of Patients Reporting Dose-Limiting Toxicity (DLT) (Phase I) — 1; 2; 3; 0 Participants
Phase 2 N=39 A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
Healthy Volunteers · Moderate to Severe Alzheimer Patients
Primary: The Primary Objective: to Evaluate the Safety and Tolerability of RPh201 After Single and Multiple Rising Doses. — 2; 2; 1; 2 Participants
Phase 2 N=301 A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI
Acute Kidney Injury
Primary: Area Under the Time Corrected Endogenous Creatinine Clearance From Day 1 to Day 7 (AUC1-7) — 41.35; 43.30; 64.25; 61.10 mL/min — p=0.949
Phase 2 N=63 Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers
Tobacco Use Disorder
Primary: Changes in a Smoking-related Gene Expression Signature Score in the Nasal Epithelium of Current Smokers — -0.15; 0.26 score on a scale
Phase 2 N=49 Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder
Methamphetamine Use Disorder
Primary: Participants Categorized as "Responders" — 11 Participants
Phase 2 N=128 Study of DA-9801 to Treat Diabetic Neuropathy
Diabetic Neuropathy
Primary: Change in Clinic Visit Pain Score at the 12 Week Visit Compared to Baseline as Assessed by the 11-point Likert Numerical Rating Scale (NRS) — 6.2; 6.6; 6.6; 6.5 Scores…
Phase 2 N=50 Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD
Osteoporosis
Primary: Change From Baseline in Bone Mineral Density (BMD) Measured by Dual-Energy X-ray Absorptiometry (DXA) — -0.0026; 0.1299; 0.1196; -0.0029 gram per centimeter squared…
Phase 2 N=136 Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Advanced Solid Tumors
Primary: Determination of Recommended Phase 2 Dose (RP2D) of BVD-523 by Dose-limiting Toxicities (DLT). — 0; 0; 0; 0 Participants
Phase 2 N=254 Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
Psoriasis · Psoriatic Arthritis · Psoriasis Arthropatica
Primary: Percentage of Participants Who Achieved a 75% Improvement (Response) From Baseline in the Psoriasis Area and Severity Index (PASI-75) at Week 16 — 7.1; 23.5; 28.2…
Phase 2 N=15 Preoperative Treatment With Cetuximab and/or IMC-A12
Head and Neck Squamous Cell Carcinoma
Primary: AKT Modulation
Phase 2 N=72 Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816
Chronic Hepatitis C
Primary: Number of Participants With Sustained Virologic Response — 70 Participants
Phase 2 N=44 Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Head and Neck Cancer · Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma · Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Primary: Overall Survival — 10.7 Months